Corcept.

Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ...WebCorcept is a biopharmaceutical company that develops cortisol modulators, drugs that block the glucocorticoid receptor (GR) and reduce cortisol levels. Corcept's products are designed to treat endocrine, metabolic, oncologic, and psychiatric disorders, such as diabetes, cancer, and depression. Corcept’s advanced clinical trials are being conducted in patients with hypercortisolism, solid tumors, amyotrophic lateral sclerosis (ALS) and liver disease (NASH).Corcept Therapeutics (Corcept) discovers, develops and commercializes innovative medicines for the treatment of psychiatric, oncologic and metabolic diseases. The company’s marketed product, Korlym (mifepristone), a cortisol receptor blocker, is indicated for the control of hyperglycemia secondary to hypercortisolism in adult patients with ...

November 2023 – PROPRIETARY – Do not republish, redistribute or modify without Corcept’s express written permission This presentation contains forward-looking statements within the meaning of the Securities Exchange Act of 1934, as amended, and the Securities Act of 1933, as amended.Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH) MENLO PARK, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a ...

Oct 26, 2023 · Corcept’s advanced clinical trials are being conducted in patients with hypercortisolism, solid tumors, amyotrophic lateral sclerosis (ALS) and liver disease (NASH).

About Corcept. Executive Team. Board of Directors. Educational Grants. Contact Us. 149 Commonwealth Drive, Menlo Park, CA 94025. Phone: 650-327-3270. Email: [email protected]. Contact us with questions about Corcept, for more information about the company, or where we are located. We are raising our 2023 revenue guidance again to a range of $470 million to $480 million, up from $455 million to $470 million. Net income was $31.4 million or $0.28 per share in the third ...Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders ...Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. Clinical trials are being conducted with the company’s leading selective ...

Cortisol. Cortisol is a hormone that modulates many physiological and psychological processes. Because of its central role in the body’s response to stress, cortisol is most commonly known as the stress hormone. It plays a key role in regulating metabolism and maintaining normal blood pressure. It affects both cognition and emotional state.

About Corcept Therapeutics. Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym ® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s ...

Corcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Forward-Looking StatementsCorcept’s first quarter 2023 revenue was $105.7 million, compared to $93.7 million in the first quarter of 2022. First quarter operating expenses were $90.8 million, compared to $66.9 million in ...Corcept leads the field in the research and development of selective glucocorticoid receptor (GR) antagonists, having discovered more than 500 proprietary molecules since being founded in 1998. Corcept is committed to improving patient lives through the discovery and development of drugs that address serious unmet medical …WebMENLO PARK, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update ...November 2023 – PROPRIETARY – Do not republish, redistribute or modify without Corcept’s express written permission This presentation contains forward-looking statements within the meaning of the Securities Exchange Act of 1934, as amended, and the Securities Act of 1933, as amended.WebJun 30, 2023 · Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. Clinical trials are being conducted with the company’s leading selective ...

Corcept is a biopharmaceutical company that develops cortisol modulators, drugs that block the glucocorticoid receptor (GR) and reduce cortisol levels. Corcept's products are designed to treat endocrine, metabolic, oncologic, and psychiatric disorders, such as diabetes, cancer, and depression. Corcept Celebrates Hispanic Trailblazers During this Hispanic Heritage Month, we honor Dr. Bernardo Alberto Houssay (1887-1971), one of three Argentinians to receive the Nobel Prize in physiology ... Jul 28, 2020 · About Corcept Therapeutics. Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Korlym ® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s ... Corcept Therapeutics Incorporated, et al., Case No. 5:19-cv-01372-LHK, which was pending in the United States District Court for the Northern District of California. Under the proposed settlement, Corcept has agreed to make a one-time payment of $14.0 million, which will be covered in full by Corcept’s insurers. About Corcept TherapeuticsWebThe Clinical Trial Manager (CTM) will independently manage all clinical aspects of a medium to large clinical study or up to two smaller clinical studies. This role will work closely with cross functional teams, vendors, sites and CRO (when applicable) to ensure compliance with protocol and the overall clinical objective.About Corcept Therapeutics. Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym ® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s ...

Data from Corcept’s 178-patient, randomized, controlled, Phase 2 trial featured in a proffered paper oral presentation at ESMO 2021; Results show statistically significant and clinically relevant benefit experienced by women with recurrent platinum-resistant ovarian cancer who were treated with nab-paclitaxel plus Corcept’s proprietary selective cortisol modulator, relacorilantCorcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. Clinical trials are being conducted with the company’s leading selective ...Web

MENLO PARK, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today …Corcept’s drug Korlym ® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Forward Looking StatementsWebCorcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. Clinical trials are being conducted with the company’s leading selective ...Corcept Therapeutics | 21,335 followers on LinkedIn. Pioneering the discovery and development of cortisol modulators. | Leading the field in the discovery of drugs that modulate the effects of ...On November 2, 2023, Joseph Lyon, the Chief Accounting Officer of Corcept Therapeutics Inc (NASDAQ:CORT), sold 5,000 shares of the company. Find the latest Corcept Therapeutics Incorporated (CORT ...Web7 Okt 2022 ... Corcept Therapeutics Extends Exclusive Specialty Pharmacy Distribution Agreement for Korlym with Optime Care.November 2023 – PROPRIETARY – Do not republish, redistribute or modify without Corcept’s express written permission This presentation contains forward-looking statements within the meaning of the Securities Exchange Act of 1934, as amended, and the Securities Act of 1933, as amended.Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Korlym was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s syndrome. Corcept …WebCorcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. Clinical trials are being conducted with the company’s leading selective ...Data from Corcept’s 178-patient, randomized, controlled, Phase 2 trial featured in a proffered paper oral presentation at ESMO 2021; Results show statistically significant and clinically relevant benefit experienced by women with recurrent platinum-resistant ovarian cancer who were treated with nab-paclitaxel plus Corcept’s proprietary …

Cortisol. Cortisol is a hormone that modulates many physiological and psychological processes. Because of its central role in the body’s response to stress, cortisol is most commonly known as the stress hormone. It plays a key role in regulating metabolism and maintaining normal blood pressure. It affects both cognition and emotional state.

Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and …

Jun 27, 2023 · Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. Clinical trials are being conducted with the company’s leading selective ... About Corcept. Executive Team. Board of Directors. Educational Grants. Contact Us. 149 Commonwealth Drive, Menlo Park, CA 94025. Phone: 650-327-3270. Email: [email protected]. Contact us with questions about Corcept, for more information about the company, or where we are located. Mar 28, 2023 · Corcept’s drug Korlym ® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Forward Looking Statements 8/3/2022. Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, reported its results for the quarter ended June 30, 2022. First.WebWe are confident in the growth potential of our Cushing’s syndrome business and are raising our 2023 revenue guidance again, to $455 - $470 million,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer. Corcept’s second quarter 2023 revenue was $117.7 million, compared to $103.4 million in the second quarter of 2022.Korlym ® (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. Important Limitations of Use.Nov 2, 2023 · We are raising our 2023 revenue guidance again to a range of $470 million to $480 million, up from $455 million to $470 million. Net income was $31.4 million or $0.28 per share in the third ... MENLO PARK, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will host an event for investors and analysts on Thursday, March 31, 2022 regarding its ovarian cancer program. Corcept will present results from the company’s 178-patient, randomized, controlled, …Corcept Therapeutics (Corcept) discovers, develops and commercializes innovative medicines for the treatment of psychiatric, oncologic and metabolic diseases. The company’s marketed product, Korlym (mifepristone), a cortisol receptor blocker, is indicated for the control of hyperglycemia secondary to hypercortisolism in adult patients with ... TPS5620 Background: Chemotherapy resistance is a major concern in the treatment of advanced platinum-resistant and platinum-refractory ovarian cancer. One mechanism of resistance is driven by cortisol, which can suppress the apoptotic pathways that chemotherapy agents rely upon, eg, suppression of BCL2 and FOXO3a pathways. …WebCorcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Forward-Looking Statements.Oval shaped, light yellow to yellow tablets debossed with “Corcept” on one side and “300” on the other side. The tablets are not scored. 4 CONTRAINDICATIONS KORLYM is contraindicated in: • Pregnancy [See Dosage and Administration (2.1), Use in Specific Populations (8.1,8.3)]Web

Corcept Therapeutics Incorporated's CORT only marketed drug, Korlym, has been approved for the once-daily oral treatment of hyperglycemia — secondary to hypercortisolism — in adult patients ...Corcept leads the field in the research and development of selective glucocorticoid receptor (GR) antagonists, having discovered more than 500 proprietary molecules since being founded in 1998. Corcept is committed to improving patient lives through the discovery and development of drugs that address serious unmet medical …WebEurofins's competitors and similar companies include Catalent, Labcorp Drug Development, Xencor and Corcept Therapeutics. Add company... Eurofins Scientific is a life sciences company providing laboratory testing services. Catalent is a company that develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies ...Instagram:https://instagram. is silver undervalueddenny's national pancake day 2023stock market labor daybest eye care insurance MENLO PARK, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today …WebCorcept leads the field in the research and development of selective glucocorticoid receptor (GR) antagonists, having discovered more than 500 proprietary molecules since being founded in 1998. Corcept is committed to improving patient lives through the discovery and development of drugs that address serious unmet medical needs related to ... meta financialswhy is vyndamax so expensive Corcept prides itself on a dynamic culture which remains true to its values while embracing continued growth and change. Our work is marked by innovation, integrity, rigor, transparent communication, and collaboration. We all have unique contributions to make, and our success is the sum of those contributions. Join us! Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. Clinical trials are being conducted with the company’s leading selective ... best financial planners near me Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Korlym was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s syndrome. Corcept …WebJun 24, 2022 · Corcept's work represents a unique opportunity for a small biopharmaceutical company. The 240-person business has largely flown under the radar since 2012, when it won its first and only Food and ...